恒指升幅曾扩至逾300点 联通及药明生物涨8%及11% 申洲破顶
市场对国会与白宫於大选前就新一轮支援经济方案达协议憧憬转趋乐观。美股期货全面续弹不足0.5%。亚太区股市普遍向好，但除菲股升1.9%报6,231连续第三天急涨外，余下升幅均少於0.8%。
本港截至8月止三个月失业率环比升0.3个百分点至6.4%逼近16年高，显高於市场预期微升至6.2%。不过，恒指连升第四天，继昨天反覆续升0.1%後，今早高开126点或0.5%报24,695，在科技股带动，升幅曾扩至333点或近1.4%，高见24,903遇压，现造24,754，续升185点或0.7%，成交额474亿元。
逾半蓝筹股造好，今天放榜的联通(00762.HK)承昨天扭三连跌重越10天线势，今早股价进一步升破牛熊线(5.75元)，最高见5.91元，现造5.84元，续涨8.1%。中移动(00941.HK)首三季纯利按年微降0.3%至816亿人民币。花旗绩後维持中移动「买入」评级及目标价76元不变，以反映股息预期和利润可见度将对股价构成提振，并料来自移动服务收入可能於末季继续回升。该股今早突破20天及10天线，最高见51.4元，现造51元，续弹2.1%。
小米-W(01810.HK)高见23.1元，现造22.75元，升2.5%。腾讯(00700.HK)四连涨，今早股价高见573元，暂受制上周三所创上市高位574元，曾倒跌低见563元，现造565.5元，续升0.2%。
阿里巴巴-SW(09988.HK)四连涨，股价稳步屡创上市新高，今早高见303.8元，现造301元，续升0.5%。传阿里旗下蚂蚁集团拟下周二开始招股，11月6日AH股同步上市。
药明生物(02269.HK)今早股价突破上周一所创上市高位218元，最高见233元，现造224元，急涨11%，成交增至790万股。内地临床阶段细胞治疗平台公司药明巨诺(JW Therapeutics)日前已开始IPO预演，据报集资额达3-3.5亿美元(高於原先规模2.3亿美元)。药明巨诺由药明生物母企药明康德(02359.HK)与美国朱诺治疗(Juno Therapeutics)共同创建。
金融股以建行(00939.HK)、工行(01398.HK)及港交所(00388.HK)表现最好，股价回升逾1%，分别高见5.68元/4.61元/373元。汇控(00005.HK)曾回升1.8%高见31.35元，现造30.9元，升0.3%。
申洲(02313.HK)先後获花旗及大摩上调目标价至160元，该股今早突破上周四所创上市高位140.4元，最高见142.1元，现造141.7元，续升2.8%。
不过，舜宇(02382.HK)延续过去三连涨势，今早进一步升至132.6元遇阻，掉头倒跌1.8%报128.8元；瑞声(02018.HK)高开报44.9元欠承接，掉头续跌1.9%报43.85元。此外，公用及地产股也全面反覆受压。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
